2023
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, Utpatel C, Cirillo D, Rodrigues C, Nilgiriwala K, Fowler P, Merker M, Niemann S, Consortium C, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Dreyer V, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grandjean L, Grazian C, Groenheit R, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Khot R, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Mansjö M, Matias D, Meintjes G, de Freitas Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Musser K, Ngcamu D, Hoang N, Niemann S, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Rodger G, Rodrigues C, Rodwell T, Roohi E, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker S, Warren R, Werngren J, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Yu X, Yang Y, Zhao Y, Yao S, Zhu B. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. The Lancet Microbe 2023, 4: e358-e368. PMID: 37003285, PMCID: PMC10156607, DOI: 10.1016/s2666-5247(23)00002-2.Peer-Reviewed Original ResearchConceptsMutation catalogueIn silico data analysisBedaquiline resistanceClofazimine resistanceResistance mechanismsProtein modelsClinical Mycobacterium tuberculosis complex isolatesImpaired DNA bindingClinically resistant strainsMinimum inhibitory concentrationVariants in vitroPacBio sequencingGenome sequenceGenomic rearrangementsGenomic variantsIn vitroExperimental evolutionGenotype dataTranscriptional repressorDrug resistance mechanismsClinical isolatesPhenotypic dataResistance determinantsDNA bindingProtein dimerisation
2017
Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?
Kunkel A, Furin J, Cohen T. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? The Lancet Infectious Diseases 2017, 17: e429-e433. PMID: 28533094, DOI: 10.1016/s1473-3099(17)30299-2.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDiarylquinolinesDrug Therapy, CombinationExtensively Drug-Resistant TuberculosisHumansConceptsUse of bedaquilineDrug-resistant tuberculosisXDR tuberculosisBedaquiline resistanceCohort study resultsMultidrug-resistant tuberculosisNew combination regimensHigh mortality rateFears of resistanceInfected contactsCombination regimensDrug combinationsPatientsEquivalent outcomesMortality rateAntituberculosis drugsBedaquilineTuberculosisNovel drugsDrug bedaquilineDrugsDiseasePopulation implicationsResistance concernsGreat need
2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation